Robert Cavorsi
Corporate Officer/Principal chez ORGANOGENESIS HOLDINGS INC.
Fortune : 131 237 $ au 30/04/2024
Postes actifs de Robert Cavorsi
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ORGANOGENESIS HOLDINGS INC. | Corporate Officer/Principal | 01/01/2021 | - |
Historique de carrière de Robert Cavorsi
Anciens postes connus de Robert Cavorsi
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Sales & Marketing | 01/01/2015 | 01/01/2016 |
Formation de Robert Cavorsi
| The Pennsylvania State University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
Opérationnelle
| Corporate Officer/Principal | 1 |
| Sales & Marketing | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ORGANOGENESIS HOLDINGS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
- Bourse
- Insiders
- Robert Cavorsi
- Expérience
